1. ScholarBank@NUS
  2. 1. Staff
  3. Staff Publications
Please use this identifier to cite or link to this item: https://doi.org/10.1038/s41467-021-26548-6
DC FieldValue
dc.titlePRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019)
dc.contributor.authorThura, Min
dc.contributor.authorAl-Aidaroos, Abdul Qader
dc.contributor.authorGupta, Abhishek
dc.contributor.authorChee, Cheng Ean
dc.contributor.authorLee, Soo Chin
dc.contributor.authorHui, Kam Man
dc.contributor.authorLi, Jie
dc.contributor.authorGuan, Yeoh Khay
dc.contributor.authorYong, Wei Peng
dc.contributor.authorSo, Jimmy
dc.contributor.authorChng, Wee Joo
dc.contributor.authorNg, Chin Hin
dc.contributor.authorZhou, Jianbiao
dc.contributor.authorWang, Ling Zhi
dc.contributor.authorYuen, John Shyi Peng
dc.contributor.authorHo, Henry Sun Sien
dc.contributor.authorYi, Sim Mei
dc.contributor.authorChiong, Edmund
dc.contributor.authorChoo, Su Pin
dc.contributor.authorNgeow, Joanne
dc.contributor.authorNg, Matthew Chau Hsien
dc.contributor.authorChua, Clarinda
dc.contributor.authorYeo, Eugene Shen Ann
dc.contributor.authorTan, Iain Bee Huat
dc.contributor.authorSng, Joel Xuan En
dc.contributor.authorTan, Nicholas Yan Zhi
dc.contributor.authorThiery, Jean Paul
dc.contributor.authorGoh, Boon Cher
dc.contributor.authorZeng, Qi
dc.date.accessioned2021-11-29T04:20:22Z
dc.date.available2021-11-29T04:20:22Z
dc.date.issued2021-11-02
dc.identifier.citationThura, Min, Al-Aidaroos, Abdul Qader, Gupta, Abhishek, Chee, Cheng Ean, Lee, Soo Chin, Hui, Kam Man, Li, Jie, Guan, Yeoh Khay, Yong, Wei Peng, So, Jimmy, Chng, Wee Joo, Ng, Chin Hin, Zhou, Jianbiao, Wang, Ling Zhi, Yuen, John Shyi Peng, Ho, Henry Sun Sien, Yi, Sim Mei, Chiong, Edmund, Choo, Su Pin, Ngeow, Joanne, Ng, Matthew Chau Hsien, Chua, Clarinda, Yeo, Eugene Shen Ann, Tan, Iain Bee Huat, Sng, Joel Xuan En, Tan, Nicholas Yan Zhi, Thiery, Jean Paul, Goh, Boon Cher, Zeng, Qi (2021-11-02). PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein (vol 10, 2484, 2019). NATURE COMMUNICATIONS 12 (1). ScholarBank@NUS Repository. https://doi.org/10.1038/s41467-021-26548-6
dc.identifier.issn20411723
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/208517
dc.description.abstractIn this article the funding from ‘Open Fund-Individual Research Grant (OF-IRG), National Medical Research Council (NMRC) Singapore with the project ID of NMRC/OFIRG/0053/2017’ was omitted.
dc.language.isoen
dc.publisherNATURE PORTFOLIO
dc.sourceElements
dc.subjectScience & Technology
dc.subjectMultidisciplinary Sciences
dc.subjectScience & Technology - Other Topics
dc.typeArticle
dc.date.updated2021-11-28T23:07:19Z
dc.contributor.departmentCANCER SCIENCE INSTITUTE OF SINGAPORE
dc.contributor.departmentBIOCHEMISTRY
dc.contributor.departmentMEDICINE
dc.contributor.departmentSURGERY
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/s41467-021-26548-6
dc.description.sourcetitleNATURE COMMUNICATIONS
dc.description.volume12
dc.description.issue1
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
PRL3zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.Thura et al.NatComm.2019.pdf4.56 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.